| IVIG–A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal … K Coffman, XJC Chen, C Okamura, E Louie IDCases 8, 27-28, 2017 | 19 | 2017 |
| Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer C Monge, C Xie, Y Myojin, K Coffman, DM Hrones, S Wang, ... Journal for Immunotherapy of Cancer 11 (2), 2023 | 16 | 2023 |
| Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE N Raj, K Coffman, T Le, RKG Do, J Rafailov, Y Choi, JF Chou, M Capanu, ... Neuroendocrinology 112 (12), 1177-1186, 2022 | 10 | 2022 |
| The current landscape of therapies for hepatocellular carcinoma K Coffman-D’Annibale, C Xie, DM Hrones, S Ghabra, TF Greten, C Monge Carcinogenesis 44 (7), 537-548, 2023 | 3 | 2023 |
| Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. KL Coffman, L Bodei, T Le, Y Choi, JF Chou, M Capanu, M Dunphy, ... Journal of Clinical Oncology 39 (3_suppl), 368-368, 2021 | 3 | 2021 |
| Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma C Monge, C Xie, Y Myojin, KL Coffman‐D'Annibale, D Hrones, G Brar, ... Cancer Medicine, 2024 | 2 | 2024 |
| Top advances of the year: Hepatobiliary cancers. KL Coffman‐D'Annibale, TF Greten Cancer (0008543X) 129 (8), 2023 | 1 | 2023 |
| A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC). C Xie, MC Monge B, D Mabry-Hrones, KL Coffman, S Hicks, B Redd, ... Journal of Clinical Oncology 41 (4_suppl), TPS624-TPS624, 2023 | 1 | 2023 |
| Analysis of the Caloric and Macronutrient Content of Meal Options Offered to Children at Popular Restaurant Chains AL Deierlein, K Coffman, L Claudio International Journal 3 (2), 109, 2014 | 1 | 2014 |
| Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC … K Coffman D'Annibale, C Ma, MC Monge B, C Xie, DM Hrones, J Awosika, ... Journal of Clinical Oncology 42 (16_suppl), e14642-e14642, 2024 | | 2024 |
| VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial K Coffman-D'Annibale, Y Myojin, C Monge, C Xie, DM Hrones, BJ Wood, ... Journal for Immunotherapy of Cancer 12 (1), 2024 | | 2024 |
| 585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial K Coffman, Y Myojin, C Monge, C Xie, DM Hrones, BJ Wood, EB Levy, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers. KL Coffman, C Xie, DM Hrones, MC Monge B, DE Kleiner, SM Steinberg, ... Journal of Clinical Oncology 41 (16_suppl), e16110-e16110, 2023 | | 2023 |
| Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy Y Myojin, B Ruf, MR Benmebarek, K Bauer, R Trehan, K Coffman, C Ma, ... Cancer Research 83 (7_Supplement), 5465-5465, 2023 | | 2023 |
| Treatment Response and Clinical Outcomes of Well-Differentiated (WD) High-Grade (HG) Neuroendocrine Tumors (NETs) to Lu-177-DOTATATE K Coffman, L Bodei, T Le, Y Choi, J Chou, M Capanu, M Dunphy, J Fox, ... PANCREAS 51 (3), E46-E46, 2022 | | 2022 |
| The Waverly Gallery KL Coffman Journal of palliative medicine 22 (7), 873, 2019 | | 2019 |
| SEPTIC SHOCK SECONDARY TO CAPNOCYTOPHAGA GINGIVALES BACTEREMIA IN AN IMMUNOCOMPETENT HOST KL Coffman, R Goldenberg JOURNAL OF GENERAL INTERNAL MEDICINE 31, S725-S726, 2016 | | 2016 |
Tim GretenNational Cancer InstituteVerified email at nih.gov
